Free Trial
OTCMKTS:PBSV

Pharma-Bio Serv 3/18/2024 Earnings Report

Pharma-Bio Serv logo
$0.50 +0.05 (+11.61%)
As of 10:16 AM Eastern

Pharma-Bio Serv EPS Results

Actual EPS
-$0.01
Consensus EPS
$0.02
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Pharma-Bio Serv Revenue Results

Actual Revenue
$2.38 million
Expected Revenue
$5.00 million
Beat/Miss
Missed by -$2.62 million
YoY Revenue Growth
N/A

Pharma-Bio Serv Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pharma-Bio Serv's next earnings date is estimated for Friday, June 13, 2025, based on past reporting schedules.

Conference Call Resources

Pharma-Bio Serv Earnings Headlines

PBSV Returns to Growth
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Pharma-Bio Serv Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharma-Bio Serv? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharma-Bio Serv and other key companies, straight to your email.

About Pharma-Bio Serv

Pharma-Bio Serv (OTCMKTS:PBSV) operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

View Pharma-Bio Serv Profile

More Earnings Resources from MarketBeat